MYUNGMOON Pharm co.,Ltd (KRX:017180)
1,722.00
+19.00 (1.12%)
At close: Aug 29, 2025
MYUNGMOON Pharm co.,Ltd Revenue
MYUNGMOON Pharm co.,Ltd had revenue of 48.76B KRW in the quarter ending June 30, 2025, with 5.81% growth. This brings the company's revenue in the last twelve months to 190.76B, up 8.16% year-over-year. In the year 2024, MYUNGMOON Pharm co.,Ltd had annual revenue of 186.44B with 9.95% growth.
Revenue (ttm)
190.76B
Revenue Growth
+8.16%
P/S Ratio
0.31
Revenue / Employee
655.54M
Employees
291
Market Cap
58.60B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 186.44B | 16.88B | 9.95% |
Dec 31, 2023 | 169.57B | 17.43B | 11.46% |
Dec 31, 2022 | 152.13B | 14.38B | 10.43% |
Dec 31, 2021 | 137.76B | 9.91B | 7.75% |
Dec 31, 2020 | 127.85B | -21.49B | -14.39% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Samsung Biologics | 5,031.69B |
Celltrion | 3,748.95B |
ALTEOGEN | 158.06B |
Yuhan | 2,165.44B |
SK Biopharmaceuticals | 620.28B |
Peptron | 5.18B |
PharmaResearch | 449.81B |
ABL Bio | 94.93B |